Solid Corp (SLDB) Cash Funds per Single Share

solidbio.com - graphic logo of issuer SLDB

Adhering to bioethical standards and minimizing bio-waste, Solid Biosciences Inc. (SLDB) is developing gene therapy. An analysis of cash per share captures liquidity dynamics, where the current status is 3.11. The business model relies on the full outsourcing of production and trials, which eliminates capital expenditures. Currently, the company is independently relaunching clinical tests, limiting interaction solely to manufacturing contracts.

Cash per Share: Solid Biosciences Inc. (SLDB) for 07/04/2022 - 11/20/2026

Analytical breakdowns for Solid Biosciences (SLDB)

- market price and analyst price targets:
- cash availability and cash flow indicators:
Summary company analysis:Solid Biosciences Inc.
Manufactured product of solidbio.com

This metric determines the proportion of cash within the capital structure, measuring the actual protection of each share against market volatility and bankruptcy. The trend in liquid assets per share confirms the ability of Solid Biosciences Inc. (SLDB) management to effectively fund the development of the SGT-003 drug, ensuring the steady advancement of the genetic engineering pipeline through strict operational expense control and a high-quality scientific foundation.

Analysis of competing companies

TEM (Tempus AI Inc) - Cash Calculated per Single Share|Cash per Share QGEN|IONS - Cash on Hand per Share|Cash Funds per Share Repligen RGEN|RNA: Cash Funds per Single Share|CRSP: Cash per Single Share|GeneDx Corp (WGS) - Cash per Single Share|RARE: Cash per Share|BEAM - Cash Funds Calculated per Share|SRPT (Sarepta Therapeutics) - Cash per Share|Cash per Single Share Twist Bioscience Inc (TWST)|Cash per Share TXG|Cash Funds Calculated per Share Intellia|Stoke - Cash per Single Share|BLFS: Cash Funds per Single Share|Wave Life Sciences Corp - Cash per Share|Maze Therapeutics, Inc. (MAZE) - Cash per Single Share|Sionna Therapeutics Inc (SION) - Cash Funds per Share|Cash per Single Share Prime Medicine Corp|Cash Funds per Share tayshagtx.com|QURE - Cash Funds Volume per Share|Cash per Single Share MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Cash Funds Volume per Share|Ocugen Corp - Cash per Single Share|PACB: Cash Funds per Single Share|benitec.com - Cash per Share|DSGN - Cash per Share|RCKT: Cash per Share|FDMT (4D Molecular Therapeutics Inc) - Cash Funds per Share|Cash per Single Share LXEO|Cash Funds per Share KRRO|Cash per Share EDIT|SLN - Cash on Hand per Share|Cash per Share PRQR (ProQR)|CDXS - Cash per Single Share|Sangamo Therapeutics Inc. - Cash per Share|NAUT - Cash per Share|MGX: Cash per Share|Cash per Single Share Precision BioSciences, Inc.|GBIO (Generation Bio) - Cash per Share|Boundless Bio Inc. (BOLD) - Cash Funds Calculated per Share|Cash per Single Share XCUR (exicuretx.com)|Imunon Inc - Cash Funds per Single Share|Cash per Share PHIO (Phio Pharmaceuticals Corp)|Amount of Cash per Share MBIO|RNAZ - Cash Funds per Share|Amount of Cash per Share BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Cash Funds per Share|Bluebird Bio - Amount of Cash per Share|IPA (ImmunoPrecise Antibodies Ltd) - Cash per Share|Cash on Hand per Share Omega Therapeutics, Inc. OMGA|Cash per Share OMIC|RGLS (Regulus Therapeutics Inc.) - Amount of Cash per Share|Cash per Share SYRS (Syros Pharmaceuticals Inc.)|Cash Calculated per Single Share TBIO (Codex DNA)|TCON - Cash Funds per Share|Cash on Hand per Share Unity Biotechnology